Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formulawhere n is 0 or 1; X is H or CN;Y is N NH or O;Z is CH2 when Y is O or N-H with Y-Z forming a single bond and Z is CH when Y is N with Y-Z forming a double bond;and wherein R1 R2 R3 and R4 are as described herein.A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor ...

This invention relates to compositions and methods utilizing a caspase-dependent chemotherapeutic drug and a PPARy-agonist such as VP-16 or Taxol as the chemotherapeutic drug and troglitazone or pioglitazone as the PPARy agonist for the treatment of cancer including glioblastoma multiforme. The present invention demonstrates that PPAR agonists work with caspase-dependent chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells.

This invention relates to compositions and methods utilizing a caspase-dependent chemotherapeutic drug and a PPARy-agonist, such as VP-16 or Taxol as the chemotherapeutic drug and troglitazone or pioglitazone as the PPARy agonist, for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that PPAR agonists work with caspase-dependent chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells.

PURPOSE: A polymer micelle drug composition is provided to effectively solubilize pioglitazone, rosiglitazone and troglitazone which are insoluble drugs. CONSTITUTION: A polymer micelle drug composition comprises amphiphilic diblock copolymer and one kind of insoluble drug. The amphiphilic diblock copolymer comprises hydrophilic block and one kind of hydrophobic block. The hydrophilic block contains polyakylene glycol. The hydrophobic block is selected among a group of polylactide, polyglycolide...

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent...

A novel process for the preparation of a compound of the formula (II) which is useful as intermediate compound for the preparation of thiazolidinedione derivatives such as rosiglitazone pioglitazone troglitazone and ciglitazone is disclosed.

A novel process for the preparation of a compound of the formula (II), which is useful as intermediate compound for the preparation of thiazolidinedione derivatives, such as rosiglitazone, pioglitazone, troglitazone and ciglitazone, is disclosed.

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1)

The present invention provides methods of preventing or reducing oxytocin-mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods describe the employment of these compounds alone or in combination with at least one other agent, such as a tocolytic agent. This offers a novel therapeutic regimen for the treatment of oxytocin-mediated actions, for example induction of uterine contractions, prostaglandin release, and milk letdown. Accord...